GE HealthCare Posts $21.8B Backlog, Leads €50.5M Cardio-Oncology Consortium
Representative Warren Davidson sold GE HealthCare shares valued between $1,001 and $15,000 on March 23, 2026. The company boasts a $21.8 billion backlog, 12.7% Pharmaceutical Diagnostics growth and will lead a €50.5 million, five-year COMPASS cardio-oncology consortium in Europe.
1. Insider Transaction
On March 23, 2026, Representative Warren Davidson disposed of GE HealthCare shares valued between $1,001 and $15,000, representing a minor position reduction unrelated to executive management decisions.
2. Strong Backlog and Diagnostics Growth
The company reported a $21.8 billion order backlog alongside 12.7% year-over-year growth in its Pharmaceutical Diagnostics segment, driven by increased demand for contrast media and PET imaging systems.
3. Leading European Cardio-Oncology Consortium
GE HealthCare secured the lead industrial role in the €50.5 million, five-year COMPASS consortium, partnering with over 60 organizations to advance precision cardio-oncology diagnostics and treatments across Europe.
4. Operational Challenges and Share Performance
Despite tariff impacts, margin pressures and uneven regional results, shares have risen 0.2% over six months versus a 20.4% sector decline, supported by robust enterprise deal momentum and a $33.3 billion market valuation.